P991: ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) POTENTIATES APOPTOSIS IN MYELOBLASTS FROM PATIENTS (PTS) WITH MYELOFIBROSIS (MF)

HemaSphere (Aug 2023)

Affiliations

Tracy Clevenger: 1 Kartos Therapeutics, Inc., Redwood City, CA, United States
Jean Cheung: 1 Kartos Therapeutics, Inc., Redwood City, CA, United States
Fanny Krantz: 1 Kartos Therapeutics, Inc., Redwood City, CA, United States
Michael Gulrajani: 1 Kartos Therapeutics, Inc., Redwood City, CA, United States
Cynthia Nguyen: 1 Kartos Therapeutics, Inc., Redwood City, CA, United States
Miranda Luarca: 1 Kartos Therapeutics, Inc., Redwood City, CA, United States
Cecile Krejsa: 1 Kartos Therapeutics, Inc., Redwood City, CA, United States
Wayne P. Rothbaum: 1 Kartos Therapeutics, Inc., Redwood City, CA, United States
Todd Covey: 1 Kartos Therapeutics, Inc., Redwood City, CA, United States

Abstract

No abstracts available.

ISSN: 2572-9241 (Online)
Publisher: Wiley
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the blood and blood-forming organs
Website: https://onlinelibrary.wiley.com/journal/25729241